Nonadherence in Hypertension: How to Develop and Implement Chemical Adherence Testing.

Détails

ID Serval
serval:BIB_4D707A5E9093
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Nonadherence in Hypertension: How to Develop and Implement Chemical Adherence Testing.
Périodique
Hypertension
Auteur⸱e⸱s
Lane D., Lawson A., Burns A., Azizi M., Burnier M., Jones DJL, Kably B., Khunti K., Kreutz R., Patel P., Persu A., Spiering W., Toennes S.W., Tomaszewski M., Williams B., Gupta P., Dasgupta I.
Collaborateur⸱rice⸱s
Endorsed by the European Society of Hypertension (ESH) Working Group on Cardiovascular Pharmacotherapy and Adherence
ISSN
1524-4563 (Electronic)
ISSN-L
0194-911X
Statut éditorial
Publié
Date de publication
01/2022
Peer-reviewed
Oui
Volume
79
Numéro
1
Pages
12-23
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
Nonadherence to antihypertensive medication is common, especially in those with apparent treatment-resistant hypertension (true treatment-resistant hypertension requires exclusion of nonadherence), and its routine detection is supported by clinical guidelines. Chemical adherence testing is a reliable and valid method to detect adherence, yet methods are unstandardized and are not ubiquitous. This article describes the principles of chemical adherence testing for hypertensive patients and provides a set of recommendations for centers wishing to develop the test. We recommend testing should be done in either of two instances: (1) in those who have resistant hypertension or (2) in those on 2 antihypertensives who have a less than 10 mm Hg drop in systolic blood pressure on addition of the second antihypertensive medication. Furthermore, we recommend that verbal consent is secured before undertaking the test, and the results should be discussed with the patient. Based on medications prescribed in United Kingdom, European Union, and United States, we list top 20 to 24 drugs that cover >95% of hypertension prescriptions which may be included in the testing panel. Information required to identify these medications on mass spectrometry platforms is likewise provided. We discuss issues related to ethics, sample collection, transport, stability, urine versus blood samples, qualitative versus quantitative testing, pharmacokinetics, instrumentation, validation, quality assurance, and gaps in knowledge. We consider how to best present, interpret, and discuss chemical adherence test results with the patient. In summary, this guidance should help clinicians and their laboratories in the development of chemical adherence testing of prescribed antihypertensive drugs.
Mots-clé
adherence, compliance, guidelines, hypertension, mass spectrometry, urine
Pubmed
Web of science
Open Access
Oui
Création de la notice
16/11/2021 9:15
Dernière modification de la notice
26/01/2022 6:35
Données d'usage